cimetidine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| histamine-H2-receptor antagonists, cimetidine derivatives | 645 | 51481-61-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.80 | g | O |
| 0.80 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 6.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 62 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 158.51 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.78 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 16, 1977 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Urine abnormality | 111.46 | 12.70 | 46 | 12925 | 5548 | 46667543 |
| Urine leukocyte esterase positive | 106.38 | 12.70 | 36 | 12935 | 2499 | 46670592 |
| Body tinea | 62.83 | 12.70 | 19 | 12952 | 916 | 46672175 |
| Lymphocyte count decreased | 60.66 | 12.70 | 53 | 12918 | 25536 | 46647555 |
| Chronic kidney disease | 53.00 | 12.70 | 61 | 12910 | 40810 | 46632281 |
| Inhibitory drug interaction | 48.72 | 12.70 | 19 | 12952 | 1976 | 46671115 |
| Urine ketone body present | 47.41 | 12.70 | 19 | 12952 | 2123 | 46670968 |
| Infection susceptibility increased | 47.10 | 12.70 | 19 | 12952 | 2160 | 46670931 |
| Blood urine present | 45.33 | 12.70 | 33 | 12938 | 12249 | 46660842 |
| Culture urine positive | 45.14 | 12.70 | 21 | 12950 | 3370 | 46669721 |
| Anaphylactoid reaction | 44.56 | 12.70 | 21 | 12950 | 3470 | 46669621 |
| Rheumatoid arthritis | 44.09 | 12.70 | 7 | 12964 | 240208 | 46432883 |
| Impaired quality of life | 42.92 | 12.70 | 20 | 12951 | 3222 | 46669869 |
| Erythema | 37.02 | 12.70 | 105 | 12866 | 142715 | 46530376 |
| Glucose tolerance impaired | 35.38 | 12.70 | 20 | 12951 | 4811 | 46668280 |
| Torsade de pointes | 34.63 | 12.70 | 28 | 12943 | 12126 | 46660965 |
| Creatinine urine decreased | 28.16 | 12.70 | 7 | 12964 | 160 | 46672931 |
| Hyperlipidaemia | 28.04 | 12.70 | 30 | 12941 | 18509 | 46654582 |
| Hypertension | 26.97 | 12.70 | 117 | 12854 | 196239 | 46476852 |
| Product dose omission issue | 26.58 | 12.70 | 7 | 12964 | 168513 | 46504578 |
| Purpura | 26.40 | 12.70 | 22 | 12949 | 9936 | 46663155 |
| Neutrophil count increased | 25.04 | 12.70 | 25 | 12946 | 14228 | 46658863 |
| Bone density decreased | 24.73 | 12.70 | 21 | 12950 | 9731 | 46663360 |
| C-reactive protein abnormal | 24.67 | 12.70 | 30 | 12941 | 21240 | 46651851 |
| Electrocardiogram T wave amplitude decreased | 22.98 | 12.70 | 7 | 12964 | 346 | 46672745 |
| Keratitis | 22.97 | 12.70 | 12 | 12959 | 2471 | 46670620 |
| Drug ineffective | 22.85 | 12.70 | 104 | 12867 | 677734 | 45995357 |
| Infusion site scar | 21.92 | 12.70 | 6 | 12965 | 202 | 46672889 |
| Poor quality sleep | 21.87 | 12.70 | 24 | 12947 | 15229 | 46657862 |
| Urticaria | 21.65 | 12.70 | 77 | 12894 | 117815 | 46555276 |
| Drug intolerance | 21.55 | 12.70 | 7 | 12964 | 147042 | 46526049 |
| Tri-iodothyronine free decreased | 21.19 | 12.70 | 6 | 12965 | 229 | 46672862 |
| Death | 20.37 | 12.70 | 161 | 12810 | 335387 | 46337704 |
| Impaired work ability | 20.09 | 12.70 | 21 | 12950 | 12615 | 46660476 |
| Red blood cells urine positive | 19.65 | 12.70 | 11 | 12960 | 2596 | 46670495 |
| Circulatory collapse | 19.60 | 12.70 | 27 | 12944 | 21597 | 46651494 |
| Food interaction | 19.54 | 12.70 | 7 | 12964 | 575 | 46672516 |
| Chromaturia | 18.76 | 12.70 | 22 | 12949 | 14997 | 46658094 |
| Band sensation | 18.46 | 12.70 | 7 | 12964 | 675 | 46672416 |
| Red cell distribution width increased | 18.33 | 12.70 | 16 | 12955 | 7688 | 46665403 |
| Joint swelling | 18.02 | 12.70 | 12 | 12959 | 166061 | 46507030 |
| Palmar-plantar erythrodysaesthesia syndrome | 17.74 | 12.70 | 25 | 12946 | 20426 | 46652665 |
| Anxiety | 16.85 | 12.70 | 97 | 12874 | 181860 | 46491231 |
| Treatment failure | 16.42 | 12.70 | 3 | 12968 | 93084 | 46580007 |
| Thyroid cyst | 16.00 | 12.70 | 6 | 12965 | 561 | 46672530 |
| Pancreatitis acute | 15.38 | 12.70 | 26 | 12945 | 24846 | 46648245 |
| Feeling hot | 15.23 | 12.70 | 33 | 12938 | 37895 | 46635196 |
| Infusion site discomfort | 15.07 | 12.70 | 6 | 12965 | 659 | 46672432 |
| Glucose urine present | 15.01 | 12.70 | 6 | 12965 | 666 | 46672425 |
| Bacterial test positive | 14.36 | 12.70 | 11 | 12960 | 4405 | 46668686 |
| Oral herpes | 14.35 | 12.70 | 22 | 12949 | 19368 | 46653723 |
| Basophil count increased | 13.76 | 12.70 | 6 | 12965 | 828 | 46672263 |
| Specific gravity urine decreased | 13.62 | 12.70 | 5 | 12966 | 440 | 46672651 |
| Blood thyroid stimulating hormone increased | 13.59 | 12.70 | 12 | 12959 | 5857 | 46667234 |
| Secondary adrenocortical insufficiency | 13.48 | 12.70 | 6 | 12965 | 869 | 46672222 |
| Skin disorder | 13.40 | 12.70 | 23 | 12948 | 22240 | 46650851 |
| Alanine aminotransferase increased | 13.12 | 12.70 | 54 | 12917 | 88397 | 46584694 |
| Lactic acidosis | 13.04 | 12.70 | 29 | 12942 | 33880 | 46639211 |
| Leukocyturia | 13.02 | 12.70 | 6 | 12965 | 942 | 46672149 |
| Product use issue | 13.01 | 12.70 | 5 | 12966 | 94639 | 46578452 |
| Protein urine present | 12.91 | 12.70 | 11 | 12960 | 5120 | 46667971 |
| Infusion site rash | 12.86 | 12.70 | 6 | 12965 | 969 | 46672122 |
| pH urine increased | 12.77 | 12.70 | 4 | 12967 | 217 | 46672874 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Chronic kidney disease | 32.44 | 15.31 | 37 | 5368 | 37801 | 29909272 |
| Palmar-plantar erythrodysaesthesia syndrome | 20.90 | 15.31 | 19 | 5386 | 14851 | 29932222 |
| Peptic ulcer | 17.53 | 15.31 | 9 | 5396 | 2759 | 29944314 |
| Adulterated product | 16.63 | 15.31 | 3 | 5402 | 21 | 29947052 |
| Renal injury | 16.51 | 15.31 | 15 | 5390 | 11714 | 29935359 |
| Flushing | 16.02 | 15.31 | 23 | 5382 | 29469 | 29917604 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BA01 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
| ATC | A02BA51 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
| FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
| FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
| CHEBI has role | CHEBI:37961 | h2-receptor blockers |
| CHEBI has role | CHEBI:49201 | anti-ulcer agents |
| CHEBI has role | CHEBI:50183 | cytochrome p450 inhibitor |
| CHEBI has role | CHEBI:60809 | adjuvants |
| MeSH PA | D000897 | Anti-Ulcer Agents |
| MeSH PA | D065609 | Cytochrome P-450 CYP1A2 Inhibitors |
| MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018494 | Histamine Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006635 | Histamine H2 Antagonists |
| MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Heartburn | indication | 16331000 | |
| Upper gastrointestinal hemorrhage | indication | 37372002 | |
| Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
| Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
| Multiple endocrine adenomas | indication | 60549007 | |
| Indigestion | indication | 162031009 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Systemic mast cell disease | indication | 397016004 | DOID:349 |
| Gastric ulcer | indication | 397825006 | DOID:10808 |
| Upper GI Bleed Prevention | indication | ||
| Maintenance of Healing Duodenal Ulcer | indication | ||
| Pancreatic insufficiency | off-label use | 37992001 | |
| Urticaria | off-label use | 126485001 | |
| Prevention of Stress Ulcer | off-label use | ||
| NSAID-Induced Gastric Ulcer | off-label use | ||
| Impaired renal function disorder | contraindication | 197663003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.83 | acidic |
| pKa2 | 6.71 | Basic |
| pKa3 | 0.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 6.14 | WOMBAT-PK | CHEMBL | |||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.92 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.15 | PDSP | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | INHIBITOR | Ki | 5.10 | IUPHAR | ||||
| Histamine H2 receptor | GPCR | Kd | 6.58 | CHEMBL | |||||
| Histamine H2 receptor | Unclassified | ANTAGONIST | Ki | 5.90 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018845 | VUID |
| N0000147147 | NUI |
| D00295 | KEGG_DRUG |
| 70059-30-2 | SECONDARY_CAS_RN |
| 4018844 | VANDF |
| 4018845 | VANDF |
| C0008783 | UMLSCUI |
| CHEBI:3699 | CHEBI |
| CHEMBL30 | ChEMBL_ID |
| CHEMBL1201051 | ChEMBL_ID |
| DB00501 | DRUGBANK_ID |
| D002927 | MESH_DESCRIPTOR_UI |
| 2756 | PUBCHEM_CID |
| 1231 | IUPHAR_LIGAND_ID |
| 3765 | INN_ID |
| 80061L1WGD | UNII |
| 152402 | RXNORM |
| 101 | MMSL |
| 2261 | MMSL |
| 4448 | MMSL |
| 4449 | MMSL |
| 6098 | MMSL |
| d00140 | MMSL |
| 003415 | NDDF |
| 004987 | NDDF |
| 373541007 | SNOMEDCT_US |
| 83051006 | SNOMEDCT_US |
| 83532008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8192 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8204 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8305 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
| Good Sense Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 0113-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0649 | SOLUTION | 300 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1298 | SOLUTION | 400 mg | ORAL | ANDA | 15 sections |
| cimetidineacid reducer | HUMAN OTC DRUG LABEL | 1 | 0363-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0053 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0317 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0372 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0541 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1282 | TABLET | 400 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-626 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-627 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-048 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 17 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-265 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-372 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-531 | TABLET | 300 mg | ORAL | ANDA | 14 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-532 | TABLET | 400 mg | ORAL | ANDA | 14 sections |
| Good Neighbor Pharmacy Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 24385-111 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
| Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 30142-323 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-024 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| TopCare Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 36800-022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-217 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-218 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Equate Cimetidine | HUMAN OTC DRUG LABEL | 1 | 49035-820 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
| SunMark heartburn reliefacid reducer | HUMAN OTC DRUG LABEL | 1 | 49348-246 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0499 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3574 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 21 sections |
| Cimetidine Hydrochloride Oral Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-050 | SOLUTION | 300 mg | ORAL | ANDA | 18 sections |